[
  {
    "ticker": "PEB",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968811",
    "id": "02968811",
    "pages": 10,
    "price_sensitive": true,
    "date": "20250714",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrlhgrd1s0s7.pdf",
    "summary": "<h3><strong>Key Material Information for Trading/Capital Markets Decisions</strong></h3>\n<h4><strong>Capital Raising Overview</strong></h4>\n<ul>\n<li><strong>Structure</strong>: Placement + Share Purchase Plan (SPP)  </li>\n<li><strong>Placement</strong>: <strong>AUD $16.1M</strong> raised (oversubscribed) at <strong>$0.10/share</strong> (18% premium to 20-day VWAP).  </li>\n<li><strong>SPP</strong>: Targeting <strong>AUD $5M</strong>, open mid-July (subject to shareholder approval).  </li>\n<li><strong>Key Dates</strong>:  </li>\n<li><strong>Annual Meeting</strong>: <strong>6 August 2025</strong> (placement approval sought).  </li>\n</ul>\n<h4><strong>Operational Highlights (Q1 26)</strong></h4>\n<ul>\n<li><strong>US Volumes</strong>: <strong>5,717 tests</strong> (-11.9% QoQ) due to transition from <em>Detect</em> to <em>Triage</em> (June 2025: <strong>77% Triage</strong> vs. 22% in Q4 25).  </li>\n<li><strong>Total Tests</strong>: <strong>6,900</strong> (-8.9% QoQ).  </li>\n<li><strong>Asia Pacific Growth</strong>: <strong>1,183 tests</strong> (+8.8% QoQ).  </li>\n<li><strong>Medicare Impact</strong>: Non-coverage determination in effect, but <strong>Kaiser Permanente volumes unaffected</strong>.  </li>\n</ul>\n<h4><strong>Medicare &amp; Regulatory Developments</strong></h4>\n<ul>\n<li><strong>Reconsideration Request</strong>: Submitted to Novitas for <em>Triage</em> (based on <strong>STRATA study</strong> + AUA Guideline).  </li>\n<li><strong>Positive discussions</strong> with Novitas (July 17 meeting for <em>Monitor</em> reconsideration).  </li>\n<li><strong>Triage Plus</strong>:  </li>\n<li><strong>Analytical validation published</strong> (93.6% sensitivity, 90.8% specificity).  </li>\n<li><strong>Target price</strong>: <strong>US$1,018</strong> (vs. $760 for <em>Triage</em>); potential commercialization post-coverage approval.  </li>\n</ul>\n<h4><strong>Commercial Wins</strong></h4>\n<ul>\n<li><strong>Optum VACCN</strong>: Secured \"in-network\" status (pays Medicare rates for veterans).  </li>\n<li><strong>Blue Cross Blue Shield</strong>: Contracting progress.  </li>\n</ul>\n<h4><strong>Cash Runway</strong></h4>\n<ul>\n<li>Capital raising extends runway <strong>&gt;12 months</strong> without Medicare coverage.  </li>\n</ul>\n<h4><strong>Upcoming Catalyst</strong></h4>\n<ul>\n<li><strong>Annual Meeting (6 August 2025)</strong>: Key votes on placement + SPP.  </li>\n</ul>\n<hr />\n<p><strong>Summary</strong>: Focus on capital raise execution, Medicare reconsideration progress, and Triage Plus commercialization. Volumes remain pressured but show resilience in non-Medicare channels.</p>",
    "usage": {
      "prompt_tokens": 7214,
      "completion_tokens": 513,
      "total_tokens": 7727,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-13T21:44:49.676216"
  },
  {
    "ticker": "SNZ",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968810",
    "id": "02968810",
    "pages": 6,
    "price_sensitive": false,
    "date": "20250714",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrlf7nq5f4mq.pdf",
    "summary": "<ul>\n<li><strong>Announcement Type</strong>: Application for quotation of new securities (employee incentive scheme)  </li>\n<li><strong>Securities Issued</strong>:  </li>\n<li><strong>Class</strong>: Ordinary Fully Paid (ASX: SNZ)  </li>\n<li><strong>Quantity</strong>: 192,360 shares  </li>\n<li><strong>Issue Date</strong>: 14/07/2025  </li>\n<li><strong>Issue Price</strong>: NZD 11.8757 per share (cash consideration)  </li>\n<li>\n<p><strong>Ranking</strong>: Equal to existing ordinary shares  </p>\n</li>\n<li>\n<p><strong>Key Management Personnel (KMP) Allocations</strong>:  </p>\n</li>\n<li>Scott Scoullar: 84 shares  </li>\n<li>\n<p>Margaret Warrington: 84 shares  </p>\n</li>\n<li>\n<p><strong>Post-Issue Capital Structure</strong>:  </p>\n</li>\n<li><strong>Total Quoted Ordinary Shares (SNZ)</strong>: 241,123,378  </li>\n<li><strong>Unquoted Securities</strong>: Bonds (375,000,000) and Options (1,358,145)  </li>\n</ul>\n<p><em>No material trading or capital markets impact beyond standard employee incentive dilution.</em></p>",
    "usage": {
      "prompt_tokens": 1489,
      "completion_tokens": 206,
      "total_tokens": 1695,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-13T21:44:37.835535"
  }
]